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Figure S1. 5-HT receptor agonists increase zebrafish sleep, related to Figure 1.  
(A-C) Activity (A), waking activity (B), and sleep (C) for zebrafish treated with DMSO vehicle (blue) or 10 μM 
quipazine (red). Line and shading represent mean ± s.e.m. n = number of animals.  
(D and E) Boxplots quantifying activity, waking activity, sleep, sleep bout number, sleep bout length during day 
(D) and night (E) and sleep latency during night (E).  
(F-J) Same as above but for animals treated with DMSO vehicle (blue) or 25 μM buspirone (red). 
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Figure S2. pCPA treatment depletes brain 5-HT and decreases sleep in zebrafish, related to Figure 1.  
 (A and B) Maximum intensity projections of dissected brains from 5 dpf zebrafish treated with either DMSO 
vehicle (A) or pCPA (B) and immunostained for 5-HT. Scale bar, 50 μm; a, anterior; p, posterior; Ra, raphe; Hyp, 
hypothalamus; Pt, pretectal area. 
(C-E) Activity (C), waking activity (D), and sleep (E) for zebrafish treated with DMSO vehicle (blue) or 7.5 μM 
pCPA (red). Line and shading represent mean ± s.e.m. n = number of animals.   
(F and G) Boxplots quantifying activity, waking activity, sleep, sleep bout number, sleep bout length during day 
(F) and night (G) and sleep latency during night (G). n = number of animals. ns p>0.05, *p<0.05, **p<0.01, ***p< 
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Figure S3. Loss of melatonin enhances the tph2 mutant zebrafish night sleep phenotype, related to 
Figure 1.  
(A) Schematic of the serotonin biosynthetic pathway in the raphe (top) where the TPH enzymatic activity 
originates exclusively from transcription of the tph2 paralog, and the melatonin biosynthetic pathway in the pineal 
gland (bottom) where the TPH enzymatic activity originates from both tph1a and tph2. aanat2 is expressed in 
the pineal and encodes for arylalkylamine N-acetyltransferase (AANAT). 
(B-D) Activity (B), waking activity (C), and sleep (D) for tph2+/-; aanat2+/- (blue), tph2-/-; aanat2+/- (cyan), tph2+/-
; aanat2-/- (red), and tph2-/-; aanat2-/- (magenta) zebrafish. Line and shading represent mean ± s.e.m. n = 
number of animals.   
(E and F) Boxplots quantifying activity, waking activity, sleep, sleep bout number, sleep bout length during day 
(E) and night (F) and sleep latency at night (F). n = number of animals. *p<0.05, **p<0.01, ***p<0.001, 
****p<0.0001, Kruskal-Wallis test followed by Dunn’s multiple comparisons test. All pair-wise comparisons were 
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Figure S4. Vehicle treatment of Tg(tph2:eNTR-YFP) animals does not affect behavior; 2-photon laser 
ablation of the raphe results in increased locomotor activity and decreased sleep in zebrafish, related to 
Figure 3. 
(A-C) Activity (A), waking activity (B), and sleep (C) for Tg(tph2:eNTR-YFP) (red) and non-transgenic sibling 
control (blue) zebrafish treated with DMSO. Line and shading represent mean ± s.e.m.  
(D and E) Boxplots quantifying activity, waking activity, sleep, sleep bout number, sleep bout length during day 
(D) and night (E) and sleep latency during night (E).  
(F) Top: Image of Tg(tph2:eGFP) fish (green channel on left, transmitted light image on right) before ablation of 
cells in red box. Bottom: Same as above but after 2-photon laser ablation; note small cavitation in transmitted 
light image (red box). The same process was repeated until all GFP+ cells in the shown area were ablated. Scale 
bar, 50 μm; a, anterior; p, posterior.  
(G-I) Activity (G), waking activity (H), and sleep (I) for raphe laser-ablated (red) and mock laser-ablated sibling 
control (blue) zebrafish. Line and shading represent mean ± s.e.m.  
(J and K) Boxplots quantifying activity, waking activity, sleep, sleep bout number, sleep bout length during day 
(J) and night (K) and sleep latency during night (K).  
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Figure S5. Tg(tph2:ChR2-YFP) zebrafish show normal wake/sleep cycles when maintained in dim 
light/dark cycles; blue light exposure does not affect behavior in zebrafish that express ChR2 in the 
pineal gland, related to Figure 4.  
(A-C) Activity (A), waking activity (B), and sleep (C) for Tg(tph2:ChR2-eGFP) (red) and non-transgenic sibling 
control (blue) zebrafish maintained in a dim light/dark cycle. Line and shading represent mean ± s.e.m. n = 
number of animals. 
(D and E) Boxplots quantifying activity, waking activity, sleep, sleep bout number, sleep bout length during day 
(D) and night (E) and sleep latency during night (E). n = number of animals. ns p>0.05, Mann-Whitney test. 
(F-H’) Maximum intensity projections of dissected brains from 5 dpf Tg(aanat2:ChR2-YFP) zebrafish 
immunostained for 5-HT and YFP. a, anterior; p, posterior; Pt, pretectal area; Hyp, hypothalamus; Ra, raphe. 
The 5-HT+ structure above the Pt is the remnants of the pineal gland that was damaged during dissection. (F’-
H’) Single plane images of the pineal gland from 5 dpf Tg(aanat2:ChR2-YFP) whole zebrafish immunostained 
for 5-HT and YFP. Scale bars, 50 μm.  
(I, J) Left: Normalized locomotor activity (I) and sleep (J) traces of 5 dpf Tg(aanat2:ChR2) zebrafish (red) and 
non-transgenic siblings (blue) before and during exposure to blue light. Right: boxplots quantifying normalized 
locomotor activity (I) and sleep (J) fold change during illumination. Line and shading represent mean ± s.e.m. 
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A Figure S6
Figure S6. Large fluorescence changes of DRNSERT-GCaMP6s, but not DRNSERT-eYFP, across and within 
behavioral states, related to Figure 5.  
(A) Fiber-tip locations of DRNSERT-ChR2 (blue) and DRNSERT-GCaMP6s (green) mice. 
(B) EMG signal and spectral analysis of EEG traces around fluorescent peaks from DRNSERT-GCaMP6s during 
NREM episodes.  
(C) Representative example from a DRNSERT-eYFP mouse of spectrogram, EMG and fiber photometry traces over 
time across different sleep-wake states. Last 5 min of ∆F/F (%) of eYFP are magnified to illustrate minor 
locomotion-induced artifacts.   
 (D) Activity level of DRNSERT averaged across normalized time per state (one-way ANOVA followed by 
Bonferroni post hoc test).  
(E) Comparison of DRNSERT activity levels early and late (10-20 and 80-90 percentile time ranges, respectively) 
within episodes of wake, NREM and REM states (paired t test).  



































































































































































































































Figure S7. Optogenetic stimulation of DRN using different transgenic mouse lines; change in delta power 
after SD of B5-B9SERT-dtA and B5-B9SERT-eYFP or B5-B9GFP mice, related to Figures 6 and 7. 
(A) Change in duration of wake state during burst or tonic stimulation of DRNSERT-ChR2 and DRNSERT-eYFP mice (n 
= 8 for DRNSERT-ChR2; n = 5 for DRNSERT-eYFP; two-sided Wilcoxon rank sum test, **p<0.01).  
(B) Change in duration of NREM state during burst or tonic stimulation of DRNSERT-ChR2 and DRNSERT-eYFP mice 
(n = 8 for DRNSERT-ChR2, n = 5 for DRNSERT-eYFP two-sided Wilcoxon rank sum test, **p<0.01, *p<0.05). 
(C-D) Quantification of viral transduction efficiency ((ChR2+ & TPH2+)/TPH2+) and ChR2-eYFP expression 
specificity ((ChR2+ & TPH2+)/ChR2+) in SERT-cre (Zhuang et al., 2005) and ePet-cre (Scott et al., 2005) mice 
(n = 8 for DRNSERT-ChR2, n = 4 for DRNePet -ChR2, paired t test, ns p>0.05, ***p<0.001). 
(E) Fiber-tip locations of ePet-cre (Scott et al., 2005) mice injected with AAV5-EF1a-DIO-ChR2-eYFP (n = 4 for 
DRNePet -ChR2). 
(F) Burst stimulation of DRNePet-ChR2 neurons. Blue box highlights laser stimulation period (n = 4 DRNePet -ChR2). 
(G) Same experiment as (F), but with prior i.p. injection of 10-20 mg/kg fluoxetine (n = 4 DRNePet -ChR2). 
(H) Tonic stimulation of DRNePet-ChR2 neurons (n = 4 DRNePet -ChR2). 
(I) Same experiment as (H), but with prior i.p. injection of 10-20 mg/kg fluoxetine (n = 4 DRNePet -ChR2). 
(J) Delta power in NREM episodes across the last 6 h of the light phase with and without prior 6 h SD of B5-
B9SERT-dtA. Delta power is shown as percentage of average delta power across all NREM episodes during the 
light phase (n = 8 for B5-B9SERT-dtA, two-sided Wilcoxon signed rank test, ns p>0.05, **p<0.01).  
 (K) Delta power in NREM episodes across the last 6 h of the light phase with and without prior 6 h SD of B5-
B9SERT-eYFP or B5-B9GFP. Delta power is shown as percentage of average delta power across all NREM episodes 
during the light phase (n = 8 for B5-B9SERT-eYFP or B5-B9GFP, two-sided Wilcoxon signed rank test, **p<0.01). Data 
represent mean ± sem.   
 
